IL138778A0 - Process for alkylating hindered sulfonamides useful in the production of matrix metalloproteinase inhibitors - Google Patents

Process for alkylating hindered sulfonamides useful in the production of matrix metalloproteinase inhibitors

Info

Publication number
IL138778A0
IL138778A0 IL13877899A IL13877899A IL138778A0 IL 138778 A0 IL138778 A0 IL 138778A0 IL 13877899 A IL13877899 A IL 13877899A IL 13877899 A IL13877899 A IL 13877899A IL 138778 A0 IL138778 A0 IL 138778A0
Authority
IL
Israel
Prior art keywords
production
matrix metalloproteinase
metalloproteinase inhibitors
sulfonamides useful
alkylating
Prior art date
Application number
IL13877899A
Other languages
English (en)
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of IL138778A0 publication Critical patent/IL138778A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/30—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and unsaturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C303/00—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides
    • C07C303/36—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of amides of sulfonic acids
    • C07C303/40—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of amides of sulfonic acids by reactions not involving the formation of sulfonamide groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
    • C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/14—Nitrogen atoms not forming part of a nitro radical
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Virology (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Psychology (AREA)
  • Communicable Diseases (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
IL13877899A 1998-04-10 1999-04-09 Process for alkylating hindered sulfonamides useful in the production of matrix metalloproteinase inhibitors IL138778A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8131098P 1998-04-10 1998-04-10
PCT/US1999/007858 WO1999052862A1 (en) 1998-04-10 1999-04-09 Process for alkylating hindered sulfonamides useful in the production of matrix metalloproteinase inhibitors

Publications (1)

Publication Number Publication Date
IL138778A0 true IL138778A0 (en) 2001-10-31

Family

ID=22163376

Family Applications (2)

Application Number Title Priority Date Filing Date
IL12916899A IL129168A (en) 1998-04-10 1999-03-25 Sulfonamides, process for their preparation and process for their reduction
IL13877899A IL138778A0 (en) 1998-04-10 1999-04-09 Process for alkylating hindered sulfonamides useful in the production of matrix metalloproteinase inhibitors

Family Applications Before (1)

Application Number Title Priority Date Filing Date
IL12916899A IL129168A (en) 1998-04-10 1999-03-25 Sulfonamides, process for their preparation and process for their reduction

Country Status (47)

Country Link
US (2) US6229025B1 (xx)
EP (2) EP0949245B1 (xx)
JP (2) JP3479511B2 (xx)
KR (2) KR100357660B1 (xx)
CN (3) CN1234396A (xx)
AP (1) AP1095A (xx)
AR (1) AR017731A1 (xx)
AT (2) ATE206392T1 (xx)
AU (2) AU755004B2 (xx)
BG (1) BG63665B1 (xx)
BR (2) BR9902219A (xx)
CA (2) CA2268684C (xx)
CO (1) CO4810299A1 (xx)
DE (2) DE69900321T2 (xx)
DK (1) DK0949245T3 (xx)
DZ (1) DZ2754A1 (xx)
EA (1) EA002277B1 (xx)
EG (1) EG21985A (xx)
ES (2) ES2163316T3 (xx)
GT (1) GT199900047A (xx)
HN (1) HN1999000043A (xx)
HR (1) HRP990106B1 (xx)
HU (2) HUP0101465A3 (xx)
ID (2) ID23244A (xx)
IL (2) IL129168A (xx)
IN (1) IN192485B (xx)
IS (1) IS5018A (xx)
MA (1) MA24833A1 (xx)
NO (1) NO991675L (xx)
NZ (1) NZ335105A (xx)
OA (1) OA11030A (xx)
PA (1) PA8469601A1 (xx)
PE (1) PE20000417A1 (xx)
PL (2) PL332451A1 (xx)
PT (1) PT949245E (xx)
RU (1) RU2197479C2 (xx)
SA (1) SA99200089A (xx)
SG (1) SG75167A1 (xx)
SK (1) SK45399A3 (xx)
TN (1) TNSN99054A1 (xx)
TR (2) TR199900756A2 (xx)
TW (1) TW520354B (xx)
UA (1) UA57039C2 (xx)
UY (1) UY25469A1 (xx)
WO (1) WO1999052862A1 (xx)
YU (1) YU18399A (xx)
ZA (2) ZA992627B (xx)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6458822B2 (en) 2000-03-13 2002-10-01 Pfizer Inc. 2-oxo-imidazolidine-4-carboxylic acid hydroxamide compounds that inhibit matrix metalloproteinases
EP1134207A1 (en) * 2000-03-15 2001-09-19 Pfizer Products Inc. Process for preparing resorcinol derivatives
JP4008708B2 (ja) 2000-04-07 2007-11-14 サムスン エレクトロニクス カンパニー リミテッド マトリックスメタロプロテイナーゼの阻害剤としてのスルホンアミド誘導体
US20020073441A1 (en) 2000-12-13 2002-06-13 Ross Brian D. Compositions and methods for detecting proteolytic activity
US6844373B2 (en) * 2002-05-28 2005-01-18 Alcatel Composition comprising fluorinated, radiation-curable dyes for surface energy control
EP2181704B1 (en) 2002-12-30 2015-05-06 Angiotech International Ag Drug delivery from rapid gelling polymer composition
ITFI20040174A1 (it) * 2004-08-03 2004-11-03 Protera S R L Derivati arilsolfonammidici dell'acido idrossammico ad azione inibitoria di metalloproteinasi
ITBO20050005U1 (it) * 2005-01-31 2006-08-01 Ali Spa Distributore di bevande ghiacciate e simili

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA794723B (en) 1978-09-11 1980-08-27 Univ Miami Anti-hypertensive agents
GB9000725D0 (en) 1990-01-12 1990-03-14 Pfizer Ltd Therapeutic agents
US5506242A (en) 1993-01-06 1996-04-09 Ciba-Geigy Corporation Arylsufonamido-substituted hydroxamic acids
US5863949A (en) * 1995-03-08 1999-01-26 Pfizer Inc Arylsulfonylamino hydroxamic acid derivatives
JP2000501423A (ja) * 1996-08-23 2000-02-08 ファイザー インク． アリールスルホニルアミノヒドロキサム酸誘導体
JP3765584B2 (ja) 1997-02-03 2006-04-12 ファイザー・プロダクツ・インク アリールスルホニルアミノヒドロキサム酸誘導体
WO1999007675A1 (en) 1997-08-08 1999-02-18 Pfizer Products Inc. Aryloxyarylsulfonylamino hydroxamic acid derivatives
DE69805473T2 (de) 1997-08-08 2003-01-16 Pfizer Products Inc., Groton Arylsulfonylaminohydroxamsäurederivate
PA8469401A1 (es) 1998-04-10 2000-05-24 Pfizer Prod Inc Derivados biciclicos del acido hidroxamico

Also Published As

Publication number Publication date
MA24833A1 (fr) 1999-12-31
WO1999052862A1 (en) 1999-10-21
CA2268684A1 (en) 1999-10-10
EA199900277A2 (ru) 1999-10-28
UY25469A1 (es) 1999-11-17
EP1068180A1 (en) 2001-01-17
JP3479511B2 (ja) 2003-12-15
EP1068180B1 (en) 2004-12-15
YU18399A (sh) 2002-11-15
BR9910110A (pt) 2001-10-09
TW520354B (en) 2003-02-11
BG63665B1 (bg) 2002-08-30
KR19990082986A (ko) 1999-11-25
TR200002950T2 (tr) 2000-12-21
HUP9901043A1 (hu) 2000-08-28
TNSN99054A1 (fr) 2005-11-10
IL129168A (en) 2003-07-06
SK45399A3 (en) 2000-08-14
PA8469601A1 (es) 2000-09-29
KR100377718B1 (ko) 2003-03-26
RU2197479C2 (ru) 2003-01-27
EP0949245A1 (en) 1999-10-13
US6229025B1 (en) 2001-05-08
DK0949245T3 (da) 2002-01-28
CN1288885A (zh) 2001-03-28
AU755004B2 (en) 2002-11-28
AP1095A (en) 2002-08-26
GT199900047A (es) 2000-09-15
ID23244A (id) 2000-03-30
CA2268684C (en) 2004-07-13
CN1296474A (zh) 2001-05-23
AU760213B2 (en) 2003-05-08
NO991675L (no) 1999-10-11
BG103320A (en) 2001-08-31
DE69922638T2 (de) 2005-05-19
JP2000026400A (ja) 2000-01-25
HN1999000043A (es) 1999-11-03
HRP990106B1 (en) 2003-08-31
SG75167A1 (en) 2000-09-19
CN1234396A (zh) 1999-11-10
JP2002511447A (ja) 2002-04-16
OA11030A (en) 2002-02-07
PL343530A1 (en) 2001-08-27
HRP990106A2 (en) 1999-12-31
IS5018A (is) 1999-10-11
ZA200005370B (en) 2002-01-03
EP0949245B1 (en) 2001-10-04
US6114568A (en) 2000-09-05
PT949245E (pt) 2002-02-28
IN192485B (xx) 2004-04-24
SA99200089A (ar) 2005-12-03
HUP0101465A2 (hu) 2002-03-28
BR9902219A (pt) 2000-04-11
IL129168A0 (en) 2000-02-17
DZ2754A1 (fr) 2003-09-15
ZA992627B (en) 2000-10-09
ES2163316T3 (es) 2002-01-16
PE20000417A1 (es) 2000-05-24
JP3540959B2 (ja) 2004-07-07
HU9901043D0 (en) 1999-06-28
CO4810299A1 (es) 1999-06-30
DE69900321D1 (de) 2001-11-08
AU2369199A (en) 1999-10-21
AP9901506A0 (en) 1999-06-30
UA57039C2 (uk) 2003-06-16
KR100357660B1 (ko) 2002-10-25
KR20010042567A (ko) 2001-05-25
ATE206392T1 (de) 2001-10-15
EG21985A (en) 2002-05-31
CA2327498A1 (en) 1999-10-21
DE69900321T2 (de) 2002-07-11
EA199900277A3 (ru) 2000-04-24
AR017731A1 (es) 2001-09-12
DE69922638D1 (de) 2005-01-20
AU3552799A (en) 1999-11-01
PL332451A1 (en) 1999-10-11
HUP0101465A3 (en) 2002-11-28
TR199900756A2 (xx) 1999-11-22
ID27208A (id) 2001-03-08
ES2234253T3 (es) 2005-06-16
CA2327498C (en) 2006-01-31
NO991675D0 (no) 1999-04-09
EA002277B1 (ru) 2002-02-28
NZ335105A (en) 2000-03-27
ATE284864T1 (de) 2005-01-15

Similar Documents

Publication Publication Date Title
PL349192A1 (en) Protease inhibitors
GB9912961D0 (en) Metalloprotease inhibitors
IL150430A0 (en) Cell division inhibitors and process for producing the same
EP1057488A4 (en) INTERLEUKIN-6 PRODUCTION INHIBITORS
HUP0200119A3 (en) Sulfamato hydroxamic acid metalloprotease inhibitor
EP1093367A4 (en) PROTEASE INHIBITORS
IL145085A0 (en) Dihetero-substituted metalloprotease inhibitors
IL144168A0 (en) 2,3,4,5,-tetrahydro-1h-[1,4] benzodiazepine-3-hydroxamic acid as matrix metalloproteinase inhibitors
IL139248A0 (en) Novel substituted aryl hydroxamic acids as metalloproteinase inhibitors
EP1067894A4 (en) PROTHEASEINHIBITOREN
IL138778A0 (en) Process for alkylating hindered sulfonamides useful in the production of matrix metalloproteinase inhibitors
IL136889A0 (en) Matrix metalloprotease inhibitors
EP1079821A4 (en) PROTEASE INHIBITORS
IL137162A0 (en) 2,3,4,5-tetrahydro -1h- [1,4]-benzodiazepine -3- hydroxamic acids as matrix metalloproteinase inhibitors
HUP0105439A2 (en) Process for the synthesis of hiv protease inhibitors
HK1041690A1 (zh) 蛋白酶抑制劑
EP1086083A4 (en) PROTEASE INHIBITORS
PL347152A1 (en) Benzamide derivatives as thrombin inhibitors
GB2385588B (en) Corrosion inhibitor compounds and process for production thereof
DE19882213D2 (de) Vorrichtung zum Herstellen von Betonsteinen
PT102299B (pt) Processo metalurgico para a utilizacao de minerais piriticos polimetalicos
SI1066276T1 (en) Process for the synthesis of hiv protease inhibitors
SI1181017T1 (en) Metalloprotease inhibitors
GB9818830D0 (en) Hydroxamic acid derivatives as proteinase inhibitors